Different Pelletization Techniques Functionality and Key Insights

Introduction to Different Pelletization Techniques and Their Functionality in Drug Formulations

Different pelletization techniques form a core part of pharmaceutical manufacturing for solid dosage forms that deliver active pharmaceutical ingredients (APIs) with enhanced performance. Pelletization, a process that generates small, uniform spherical particles, improves flow properties, enables controlled or delayed release, and reduces local irritation in the gastrointestinal tract compared with conventional tablets and capsules. These techniques include direct pelletization, layering pelletization, extrusion-spheronization, spray drying, and other advanced methods, each offering specific functional benefits. Direct pelletization allows quick single-step formation with minimal equipment and lower cost. Layering pelletization deposits drug onto inert cores to improve drug loading and modify release profiles. More complex methods like extrusion-spheronization yield highly uniform pellets but require more processing time. Across all approaches, the choice of technique affects drug dissolution, stability, and manufacturability, and each technique opens opportunities to tailor drug release, enhance bioavailability, and optimize patient compliance through multiparticulate delivery systems.

Summary of the Thesis

The PhD thesis [1] “Application of High-Shear Granulator in Different Pelletization Techniques” by Azza Asim Khalid Mahmoud explores high-shear granulator applications. Furthermore, it demonstrates how these granulators improve different pelletization techniques to produce optimized drug delivery pellets. Consequently, different pelletization techniques become essential for solid dosage forms, enhancing flow properties and ensuring uniform size distribution. Moreover, the study highlights how these techniques enable precise control over drug release while equipment choice reduces cost and streamlines production. In addition, both direct pelletization and layering pelletization are analyzed within a high-shear granulator framework. Therefore, Quality by Design (QbD) principles guide the definition of process parameters that impact pellet quality. Through risk assessments, design of experiments (DoE), and optimization strategies, critical parameters are identified. These include impeller speed, chopper speed, binder volume, and granulating liquid, which strongly affect pellet size, yield, hardness, and dissolution. Overall, the research confirms that mastering different pelletization techniques enhances pharmaceutical pellet formulation efficiency and performance.

Direct pelletization with high-shear granulation

The thesis demonstrates that direct pelletization with high-shear granulation can produce pellets with desirable physical attributes and consistent drug distribution through careful experimental design. By applying a full factorial design and central composite design, the author constructs an optimal design space. The study also incorporates active pharmaceutical ingredients—amlodipine besylate and hydrochlorothiazide—showing how optimized pellets retain good content uniformity and dissolution performance when loaded. On the layering pelletization front, MCC cores serve as a base for drug deposition, with micro-computed tomography and thermal analysis confirming structural features that contribute to improved drug release. The research highlights how the high-shear granulator facilitates physical transformations such as partial amorphization of loaded drugs, which can enhance dissolution rates.

The thesis underscores the advantages of integrating QbD concepts into pelletization, improving reproducibility and understanding of how process variables interact. Overall, the study provides a comprehensive view of how different pelletization techniques benefit from high-shear granulation to produce robust pellet formulations with desirable critical quality attributes.

Use of CELLETS® in the Study

Within the thesis, CELLETS®—spherical microcrystalline cellulose cores—play a key role in the layering pelletization process. These inert cores are typically defined in uniform sizes of approximately 100 µm to 1400 µm. They provide a stable and consistent substrate onto which drug combinations (hydrochlorothiazide and amlodipine besylate) are deposited under high-shear conditions. The application of CELLETS® enhances layering efficiency, facilitates uniform drug distribution, and contributes to improved pellet morphology and mechanical integrity. Their use is integral to investigating how high-shear granulation affects drug layering and the resulting pharmacotechnical properties of the pellets.

Conclusion and Outlook

This thesis confirms that different pelletization techniques, particularly direct and layering methods, gain substantial functional advantages when implemented with high-shear granulation and QbD strategies. The research shows that such integration leads to pellets with optimized size, mechanical strength, and drug release characteristics. Moreover, the use of CELLETS® strengthens drug layering approaches and helps maintain uniformity in multiparticulate systems. Future research may expand on scaling these methods for commercial production, exploring additional API combinations. They are employing real-time monitoring technologies to further enhance control over pellet quality. By advancing the understanding of how process parameters affect critical quality attributes, this work positions high-shear granulation. This technology is a versatile tool for modern drug formulation technologies.

References

[1] SZTE Repository of Dissertations

Different Pelletization Techniques Functionality and Key Insights

Enzyme-cleavable methadone prodrugs Innovations in formulation

Enzyme‑cleavable methadone prodrugs: Functionality, Opportunities, and Summary of US20250361205A1

Introduction to Enzyme‑cleavable methadone prodrugs

Enzyme‑cleavable methadone prodrugs represent a novel class of pharmacological agents designed to provide controlled release of methadone only after specific enzymatic activation. These prodrugs attach an enzyme‑cleavable promoiety to the methadone molecule, rendering it inactive until a target enzyme cleaves the linkage in vivo. This mechanism reduces misuse potential and provides more predictable pharmacokinetics compared to conventional methadone formulations. By depending upon specific enzymatic activity, this prodrug design can improve safety and minimize risks associated with inappropriate administration or overdose, while maintaining therapeutic efficacy for opioid dependence or chronic pain management.

Beyond safety, enzyme‑cleavable methadone prodrugs offer opportunities in advanced drug formulation. They enable precise control over the timing and extent of methadone release based on the activity of endogenous enzymes. As a result, formulators can tailor release rates and reduce systemic peaks that commonly contribute to adverse effects or abuse. These prodrugs also permit formulation with excipients or technologies that further modulate release profiles, including multiparticulate systems or coatings. In addition, controlled enzyme activation provides a strategy to optimize oral delivery, enhance patient compliance, and potentially reduce the burden of supervised dosing programs in opioid maintenance therapy.

Summary of this patent

The patent application US20250361205A1 discloses enzyme‑cleavable methadone prodrugs and corresponding methods of use, focusing on prodrugs that deliver methadone through enzymatically‑controlled release. These prodrugs contain a promoiety linked to methadone that requires cleavage by specific enzymes, such as digestive proteases, before the active opioid is liberated. By requiring enzymatic cleavage followed by intramolecular cyclization to release active methadone, the design significantly lowers the susceptibility to accidental or intentional misuse, including inappropriate routes of administration or chemical tampering.

The disclosed prodrug moieties can include amino acid residues or peptides of up to about 100 amino acids linked via an amide bond to the methadone nitrogen. By selecting promoieties that are substrates for particular enzymes, formulators can adjust release kinetics based on the target enzyme’s activity and distribution. For example, gastrointestinal enzymes like trypsin are contemplated as triggers for prodrug activation. The application also describes including enzyme inhibitors in the pharmaceutical composition to attenuate the rate of enzymatic cleavage when desired. This addition can further control release profiles and reduce unintended rapid activation.

The patent describes general chemical structures of enzyme‑cleavable methadone prodrugs, outlining variations in functional groups and linkers that influence both stability and enzymatic susceptibility. These structures include several formulae (e.g., MD‑(I), MD‑(II), MD‑(III)), each representing different classes of promoieties attached to the methadone core. Notably, upon enzymatic cleavage of the promoiety, a stable cyclic urea or other cyclic group forms, which is pharmaceutically acceptable and of low toxicity. The description also covers pharmaceutically acceptable salts, solvates, and crystalline forms of the prodrugs, enhancing formulation versatility.

A key advantage emphasized in this disclosure is the reduction of excessive plasma methadone levels when the prodrug is administered improperly. Because the prodrug cannot be converted to methadone without specific enzymatic action and cyclization, the risk of overdose is reduced. Furthermore, the document details that trypsin inhibitors or other enzyme modulators may be co‑formulated to regulate the enzymatic activation rate. In addition to the chemical and pharmacokinetic considerations, the application mentions pharmaceutical compositions that include typical excipients, such as fillers, binders, and disintegrants, that support conventional formulation processes for oral delivery.

Use of CELLETS® in This Context

Although CELLETS® (highly spherical microcrystalline cellulose pellets used as starter cores in multiparticulate drug delivery systems) are not explicitly referenced in US20250361205A1, the broader formulation context suggests potential relevance. CELLETS® provide uniform and inert starter cores that support controlled layering of active pharmaceutical ingredients. In multiparticulate systems, CELLETS® improve coating uniformity, flow properties, and controlled release profiles in oral dosage forms. These characteristics make them useful for advanced prodrug formulations where release kinetics and consistency are critical, particularly when precise layering of enzyme‑cleavable prodrug moieties is required. Unlike conventional inert cores, CELLETS® enable predictable performance and facilitate scalable manufacturing for complex oral formulations.

In this patent, some particle sizes of CELLETS® are explicitely named:

Type Particle size distribution
(≥ 85 %)
learn more
CELLETS® 100 100-200 µm
(150/80)
more information
CELLETS® 200 200-355 µm
(80/50)
more information
CELLETS® 350 350-500 µm
(50/35)
more information
CELLETS® 500 500-710 µm
(35/25)
more information
CELLETS® 700 700-1000 µm
(25/18)
more information
CELLETS® 1000 1000-1400 µm
(18/13)
more information

Conclusion and Outlook

In summary, enzyme‑cleavable methadone prodrugs offer a promising advancement in opioid therapy and formulation science, combining controlled enzymatic activation with enhanced safety. The patent US20250361205A1 details chemical constructs and methods that reduce misuse potential and allow sophisticated control of drug release. Given ongoing needs for safer opioid medications, these prodrugs could transform maintenance therapy and pain management by minimizing overdose risks and improving patient compliance. Looking forward, integrating technologies such as multiparticulate delivery systems and optimized excipients (e.g., CELLETS®) will further refine dosing precision and therapeutic outcomes. Future research and clinical evaluation will determine how these designs perform in real‑world settings, including their impact on pharmacokinetics, abuse deterrence, and commercial viability.

Patent Summary

  • Name of Patent: Enzyme-cleavable methadone prodrugs and methods of use thereof
  • Patent Number: US20250361205A1
  • Year of Patent: 2025
  • Patent Holders: Lynn Kirkpatrick
  • Affiliation: Ensysce Biosciences Inc.

Enzyme-cleavable methadone prodrugs Innovations in formulation